These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20133122)

  • 21. The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response.
    Iakovleva I; Begum A; Pokrzywa M; Walfridsson M; Sauer-Eriksson AE; Olofsson A
    PLoS One; 2015; 10(5):e0128222. PubMed ID: 26020516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
    Sekijima Y; Kelly JW; Ikeda S
    Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
    Hammarström P; Jiang X; Deechongkit S; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
    Zhao L; Buxbaum JN; Reixach N
    Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
    Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
    PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
    Sekijima Y; Dendle MA; Kelly JW
    Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TTR fibril formation inhibitors: is there a SAR?
    Nencetti S; Orlandini E
    Curr Med Chem; 2012; 19(15):2356-79. PubMed ID: 22471984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
    Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
    Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
    J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?
    Zhong B; Huang X; Zheng Y; Guo X; Wu L
    Future Med Chem; 2021 Dec; 13(23):2083-2105. PubMed ID: 34633220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants.
    Rosen HN; Moses AC; Murrell JR; Liepnieks JJ; Benson MD
    J Clin Endocrinol Metab; 1993 Aug; 77(2):370-4. PubMed ID: 8345041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.
    Qiang L; Guan Y; Li X; Liu L; Mu Y; Sugano A; Takaoka Y; Sakaeda T; Imbimbo BP; Yamamura KI; Jin S; Li Z
    Amyloid; 2017 Mar; 24(1):42-51. PubMed ID: 28393633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.
    Johnson SM; Connelly S; Fearns C; Powers ET; Kelly JW
    J Mol Biol; 2012 Aug; 421(2-3):185-203. PubMed ID: 22244854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cooperative stabilization of transthyretin by clusterin and diflunisal.
    Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
    Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer.
    Iakovleva I; Begum A; Brännström K; Wijsekera A; Nilsson L; Zhang J; Andersson PL; Sauer-Eriksson AE; Olofsson A
    PLoS One; 2016; 11(4):e0153529. PubMed ID: 27093678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
    Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
    J Mol Biol; 2001 Mar; 306(4):733-44. PubMed ID: 11243784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
    Arsequell G; Planas A
    Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
    Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
    J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
    Iakovleva I; Brännström K; Nilsson L; Gharibyan AL; Begum A; Anan I; Walfridsson M; Sauer-Eriksson AE; Olofsson A
    J Med Chem; 2015 Aug; 58(16):6507-15. PubMed ID: 26214366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.